<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tympanostomy tube otorrhea in children: Causes, prevention, and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tympanostomy tube otorrhea in children: Causes, prevention, and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tympanostomy tube otorrhea in children: Causes, prevention, and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Glenn C Isaacson, MD, FAAP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna H Messner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tympanostomy tube otorrhea (TTO) may occur immediately after tube insertion from an existing infection in the middle ear (acute otitis media [AOM]) or later with subsequent middle ear infections or infectious processes in the ear canal.</p><p>The prevention and management of TTO in children are discussed here. An overview of TT placement and the postoperative care of children with TTs is provided separately. The indications for TT placement (eg, recurrent AOM, otitis media with effusion, and chronic suppurative otitis media) are also discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6305.html" rel="external">"Overview of tympanostomy tube placement, postoperative care, and complications in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6009.html" rel="external">"Acute otitis media in children: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5959.html" rel="external">"Acute otitis media in children: Treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5998.html" rel="external">"Acute otitis media in children: Prevention of recurrence"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5966.html" rel="external">"Otitis media with effusion (serous otitis media) in children: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/87008.html" rel="external">"Otitis media with effusion (serous otitis media) in children: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13590.html" rel="external">"Chronic suppurative otitis media (CSOM): Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/91002.html" rel="external">"Chronic suppurative otitis media (CSOM): Treatment, complications, and prevention", section on 'Aural toilet'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY</span></p><p class="headingAnchor" id="H3"><span class="h2">Tympanostomy tube otorrhea</span><span class="headingEndMark"> — </span>Tympanostomy tube otorrhea (TTO; also called post-tympanostomy tube otorrhea [PTTO]), is defined as active drainage through an existing TT [<a href="#rid1">1</a>]. TTO is primarily caused by a bacterial infection. TTO can be categorized according to its timing [<a href="#rid2">2,3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Early-onset TTO occurs within two weeks of tube placement</p><p class="bulletIndent1"><span class="glyph">●</span>Late-onset TTO occurs &gt;2 weeks after tube placement</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic or persistent TTO usually refers to otorrhea lasting for ≥6 to 8 weeks</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent TTO refers to distinct episodes of TTO between which the otorrhea clears</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Chronic suppurative otitis media</span><span class="headingEndMark"> — </span>Chronic suppurative otitis media (CSOM) is defined as purulent otorrhea that lasts for longer than six weeks despite treatment [<a href="#rid1">1</a>]. It may result from an unresolved or complicated acute otitis media (AOM) with perforation of the tympanic membrane or from a preexisting perforation. CSOM is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/13590.html" rel="external">"Chronic suppurative otitis media (CSOM): Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/91002.html" rel="external">"Chronic suppurative otitis media (CSOM): Treatment, complications, and prevention"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">PREVENTION OF TYMPANOSTOMY TUBE OTORRHEA</span></p><p class="headingAnchor" id="H6"><span class="h2">Early onset</span><span class="headingEndMark"> — </span>Approximately 10 to 20 percent of children who undergo TT placement develop early-onset otorrhea due to bacterial infection, which increases the risk of tube occlusion [<a href="#rid2">2,4</a>]. Given the frequency of this complication, our practice is to routinely administer ear drops in the postoperative period to prevent early-onset TTO. However, there is a lack of consensus among otolaryngologists regarding whether prophylaxis against early-onset tube otorrhea is routinely warranted, which ear drops are most effective and least harmful, and what dosing regimen should be used [<a href="#rid5">5</a>]. Our suggested approach differs from the guidelines of the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF), which recommend against the routine use of topical antibiotics in the perioperative setting [<a href="#rid6">6</a>]. Alternative options for prevention of early TTO include intraoperative multiple <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> washouts or an intraoperative single-dose application of topical antibiotic (with or without corticosteroid) [<a href="#rid7">7-9</a>]. While all of these interventions have been shown to reduce the risk of early TTO compared with no prophylaxis, few studies have directly compared the different approaches to one another. The beneficial effect of prophylaxis appears to be more pronounced among patients who have middle ear effusion at the time of TT insertion [<a href="#rid7">7,10,11</a>].</p><p>Our usual approach to perioperative prophylaxis is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>At the time of surgery</strong> – We typically use <a class="drug drug_pediatric" data-topicid="12670" href="/d/drug information/12670.html" rel="external">oxymetazoline</a> nasal spray (five drops) intraoperatively, which also helps achieve hemostasis at the incision site. </p><p></p><p class="bulletIndent1">Our preference for <a class="drug drug_pediatric" data-topicid="12670" href="/d/drug information/12670.html" rel="external">oxymetazoline</a> (which is a commonly used topical nasal decongestant solution) at surgery is based on its low cost, its favorable safety profile, and observational data that suggest that it is equally effective in preventing early TTO compared with topical antibiotics (ie, <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>) [<a href="#rid12">12</a>]. Systemic side effects are not seen with ototopic use of this medication at this dose, since little of the medication comes into contact with the mucous membrane. In addition, the medication does not appear to cause ototoxicity, based on a single animal study [<a href="#rid13">13</a>]. Though oxymetazoline causes stinging and discomfort in the ear when used in an awake patient, this is not a concern when it is used in the operating room. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperatively</strong> – We suggest topical fluoroquinolone drops (<a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">ofloxacin</a> or <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>) for postoperative prophylaxis [<a href="#rid14">14</a>]. The dose and duration of treatment depend on whether there is active infection at the time of surgery:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients <strong>without evidence of active middle ear infection</strong> at the time of surgery (ie, dry ears or those with serous or mucoid middle ear effusions), we instruct the family to instill three drops into the ear twice daily for three days postoperatively. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients <strong>with active middle ear infection</strong> at the time of surgery, we prescribe the antibiotic drops at treatment doses (eg, <a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">ofloxacin</a> or <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>, with or without steroid, four drops instilled into the ear twice daily for five to seven days).</p><p></p><p class="bulletIndent1">If cost is a limitation, generic <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> eye drops can be used as a low-cost alternative. Both the otic and ophthalmologic preparations of topical fluoroquinolone drops are stable at room temperature for at least four months, so parents can be instructed to keep the remaining solution to use at a later time should the child require subsequent treatment for TTO [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1">The use of topical antibiotics in this setting has been studied in randomized trials and meta-analyses, which reached variable conclusions [<a href="#rid7">7,8,11,16</a>]. A systematic review and meta-analysis identified 11 randomized and quasi-randomized trials of various topical antibiotics compared with no prophylaxis postoperatively in children undergoing TT placement [<a href="#rid7">7</a>]. Most of the trials had serious methodologic limitations (ie, lack of blinding, incomplete follow-up). In the three trials (n=928 children) that were deemed to be of high methodologic quality, postoperative administration of antibiotic drops reduced the incidence of otorrhea in all three trials (absolute reduction ranged from 7 to 34 percent). A subsequent randomized trial published after the meta-analysis did not detect a statistically significant reduction in the rate of early otorrhea in patients treated postoperatively with topical <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> compared with normal <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> (17 versus 24 percent, respectively) [<a href="#rid16">16</a>]. However, there was a high rate of loss to follow-up (36 percent), which may have limited the ability to detect a significant effect.</p><p></p><p class="bulletIndent1">Alternative options for prevention of early-onset TTO that have demonstrated efficacy based on randomized clinical trials and meta-analyses include the following [<a href="#rid7">7-9</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intraoperative multiple <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> washouts</p><p class="bulletIndent2"><span class="glyph">•</span>Intraoperative single-dose application of topical drops (antibiotic with or without a corticosteroid)</p><p class="bulletIndent2"><span class="glyph">•</span>Oral antibiotics</p><p></p><p class="bulletIndent1">There are insufficient data, particularly head-to-head comparisons, to determine which ear drops (eg, <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a>, antibiotic alone, combination antibiotic/corticosteroid, <a class="drug drug_pediatric" data-topicid="12670" href="/d/drug information/12670.html" rel="external">oxymetazoline</a>) are most efficacious for preventing early postsurgical otorrhea [<a href="#rid10">10,12,17-20</a>]. We prefer topical fluoroquinolone drops because of their favorable safety profile.</p><p></p><p class="bulletIndent1">Potential toxicity is also an important consideration. One trial (involving aminoglycoside ear drops) included in the meta-analysis assessed ototoxicity and found no effect on hearing. Two subsequent randomized controlled trials of <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> otic suspension also found no evidence of ototoxicity [<a href="#rid8">8,9</a>].</p><p></p><p class="bulletIndent1">The only agent specifically approved by the US Food and Drug Administration for use at the time of TT insertion to prevent TTO is 6% <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> gel [<a href="#rid21">21</a>]. An industry-sponsored phase 3 trial suggested efficacy compared with no treatment [<a href="#rid9">9</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Late onset and recurrent</span><span class="headingEndMark"> — </span>Approximately 30 percent of children who undergo placement of TTs have at least one episode of late-onset TTO while the tube remains in place  (<a class="graphic graphic_picture graphicRef64324" href="/d/graphic/64324.html" rel="external">picture 1</a>), and 7 percent develop recurrent TTO [<a href="#rid2">2</a>]. (See <a class="local">'Acute tympanostomy tube otorrhea'</a> below and <a class="local">'Chronic tympanostomy tube otorrhea'</a> below.)</p><p>Prevention of recurrent TTO in young children during the winter months (ie, cold and flu season) involves the same measures used to control recurrent acute otitis media (AOM) in infants and young children. (See <a class="local">'Risk factors'</a> below and  <a class="medical medical_review" href="/d/html/5998.html" rel="external">"Acute otitis media in children: Prevention of recurrence"</a>.)</p><p>These measures include [<a href="#rid22">22-24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Handwashing (see  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Hand hygiene'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunization against <em>Streptococcus</em> <em>pneumoniae</em> and influenza (<em>S</em>. <em>pneumoniae</em> immunization is part of the universal immunization schedule for infants and young children in the United States; influenza vaccination is recommended for all children aged six months and older) (see  <a class="medical medical_review" href="/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines", section on 'Target groups'</a> and  <a class="medical medical_review" href="/d/html/6053.html" rel="external">"Pneumococcal vaccination in children", section on 'Routine immunization for children &lt;5 years'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Withdrawal from daycare, if feasible</p><p></p><p>The effect of prophylactic antibiotics in the prevention of TTO has not been studied [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H141472595"><span class="h2">Water precautions</span><span class="headingEndMark"> — </span>The need for water precautions (eg, the use of ear plugs, swimming caps, or antibiotic-containing ear drops) in children with TTs is discussed separately. (See  <a class="medical medical_review" href="/d/html/6305.html" rel="external">"Overview of tympanostomy tube placement, postoperative care, and complications in children", section on 'Water precautions'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">ACUTE TYMPANOSTOMY TUBE OTORRHEA</span><span class="headingEndMark"> — </span>Acute TTO in children refers to TTO that lasts less than six weeks. It usually results from acute otitis media (AOM) following an upper respiratory infection or from the introduction of contaminated water from the ear canal into the middle ear.</p><p class="headingAnchor" id="H11"><span class="h2">Pathogens</span><span class="headingEndMark"> — </span>In children two years and younger, acute TTO is usually caused by the same pathogens that cause AOM in children without tubes (eg, <em>S</em>. <em>pneumoniae</em>, <em>Moraxella</em> <em>catarrhalis</em>, and <em>Haemophilus</em> <em>influenzae</em>) [<a href="#rid26">26-30</a>]. <em>Pseudomonas</em> <em>aeruginosa</em> and <em>Staphylococcus</em> <em>aureus</em> are more prevalent in cases of TTO that persist despite oral antibiotic therapy and in older children in whom TTO is usually induced by water penetration [<a href="#rid26">26,27,30,31</a>]. Gram-negative organisms such as <em>Pseudomonas</em> and <em>Eikenella</em> are more common when granulation tissue is present [<a href="#rid32">32</a>]. One study found methicillin-resistant <em>S</em>. <em>aureus</em> (MRSA; in 6 percent of TTO) [<a href="#rid33">33</a>]. Most cases of TTO are polymicrobial, and viruses are isolated in approximately 20 percent [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/6021.html" rel="external">"Acute otitis media in children: Epidemiology, microbiology, and complications", section on 'Microbiology'</a>.)</p><p class="headingAnchor" id="H713006041"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>The risk of early- and late-onset otorrhea depends upon patient and environmental factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Early onset – The risk of early postoperative otorrhea is increased among children younger than two years of age and children with inflamed middle ear mucosa, mucoid effusion, and bacterial pathogens in the ear canal or middle ear effusion at the time of surgery [<a href="#rid34">34,35</a>]. However, the rate of early postoperative otorrhea is not affected by surgical technique or preparation of the ear canal [<a href="#rid34">34,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late onset – Infants and young children with tubes inserted to control recurrent episodes of AOM are more likely to experience late-onset otorrhea than older children who have tubes inserted for otitis media with effusion (chronic otitis media) [<a href="#rid35">35</a>]. In temperate climates, TTO occurs most often during the winter months in young children and the summer months in older children, coinciding with upper respiratory infection season and swimming season, respectively [<a href="#rid26">26</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>Untreated acute TTO resolves spontaneously in at least one-half of children within 14 days of onset [<a href="#rid37">37</a>]. Its long-term natural history is unknown. Similarly, viral myringitis (tympanic membrane erythema without purulent infection) and early AOM may resolve spontaneously without drainage because the tube provides middle ear ventilation.</p><p class="headingAnchor" id="H13"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The treatment of acute TTO in children depends upon the age of the child, clinical status, and most likely pathogens. Uncomplicated cases are typically treated with topical antibiotic ear drops with or without corticosteroids, and oral or parenteral antibiotics are reserved for children with a concurrent infection (eg, sinusitis, streptococcal pharyngitis, adjacent auricular cellulitis) or blocked external auditory canal or those who are immunocompromised [<a href="#rid6">6,38</a>]. Patients are usually treated empirically, with culture of the middle ear fluid reserved for patients with refractory disease or ill-appearing infants with concomitant systemic infection. Aural toilet (ie, suctioning copious discharge, either by a primary care clinician using a short 8-French suction catheter or by an otolaryngologist using an operating microscope to guide a metal suction tube) aids in penetration of ototopic drops and may hasten resolution [<a href="#rid1">1,39</a>]. (See  <a class="medical medical_review" href="/d/html/91002.html" rel="external">"Chronic suppurative otitis media (CSOM): Treatment, complications, and prevention", section on 'Aural toilet'</a>.)</p><p class="headingAnchor" id="H797278"><span class="h3">Uncomplicated acute tympanostomy tube otorrhea</span></p><p class="headingAnchor" id="H384296498"><span class="h4">Choice of therapy</span><span class="headingEndMark"> — </span>For children with uncomplicated acute TTO (ie, without systemic symptoms, occlusion of the auditory canal, auricular cellulitis, or immunocompromise), we suggest topical therapy with ear drops containing a fluoroquinolone plus a corticosteroid (eg, <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> and <a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> otic suspension, four drops into the affected ear twice daily for five to seven days). Observation is also an option for such patients since many of these episodes resolve spontaneously [<a href="#rid2">2,40</a>]. However, topical therapy should be given if the otorrhea does not resolve within one week. (See <a class="local">'Natural history'</a> above.)</p><p>Fluoroquinolone-containing drops (eg, <a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">ofloxacin</a>, <a class="drug drug_pediatric" data-topicid="12922" href="/d/drug information/12922.html" rel="external">ciprofloxacin-dexamethasone</a>, <a class="drug drug_pediatric" data-topicid="114895" href="/d/drug information/114895.html" rel="external">ciprofloxacin-fluocinolone</a> acetonide) are preferred over aminoglycoside ear drops due to their broad antimicrobial spectrum, lower risk of ototoxicity, lower rate of contact dermatitis, and twice-daily dosing [<a href="#rid3">3,18,41-44</a>]. Compared with oral <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a>, topical fluoroquinolone has the advantage of providing activity against <em>P</em>. <em>aeruginosa</em>, a common pathogen in TTO, particularly in older children (see <a class="local">'Pathogens'</a> above). Fluoroquinolone-containing drops are the only topical antimicrobials approved by the US Food and Drug Administration for treating otorrhea with a nonintact tympanic membrane. Although fluoroquinolones are generally thought to be safe and less ototoxic (compared with aminoglycosides), retrospective studies suggest that they may increase the risk of persistent tympanic membrane perforation [<a href="#rid45">45,46</a>].</p><p>Addition of a corticosteroid to the antibiotic preparation enhances cure when granulation tissue is present  (<a class="graphic graphic_picture graphicRef107997" href="/d/graphic/107997.html" rel="external">picture 2</a>) [<a href="#rid41">41,47</a>]. In addition, the topical corticosteroid may modestly improve the efficacy of the antibiotic [<a href="#rid48">48</a>]. The available steroid-containing ototopical preparations are fairly costly, and some insurers may not cover them. If cost is an issue, generic <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> 0.3% eye drops can be used in the ear with similar effect as the ototopical preparations [<a href="#rid49">49</a>].</p><p>If the child fails to respond with resolution of visible otorrhea after seven days of topical therapy, a trial of oral antimicrobial therapy or referral to a pediatric otolaryngologist for cleaning of the tube orifice and culture of the middle ear fluid may be warranted. (See <a class="local">'Complicated acute tympanostomy tube otorrhea'</a> below and <a class="local">'Chronic tympanostomy tube otorrhea'</a> below.)</p><p>The efficacy and safety of combined topical fluoroquinolone plus corticosteroid therapy for acute TTO is supported by several randomized trials [<a href="#rid37">37,48,50-53</a>]. In one trial comparing topical <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>/<a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> with oral <a class="drug drug_pediatric" data-topicid="12631" href="/d/drug information/12631.html" rel="external">amoxicillin</a>/clavulanate, topical therapy resulted in shorter duration of otorrhea (four versus seven days) and higher rate of clinical cure (85 versus 59 percent) [<a href="#rid50">50</a>]. Similar findings were noted in a trial comparing topical <a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">ofloxacin</a> with oral amoxicillin/clavulanate [<a href="#rid51">51</a>]. In both trials, topical therapy was better tolerated than oral antibiotic therapy. In another randomized trial, treatment with combined topical ciprofloxacin plus corticosteroid (<a class="drug drug_pediatric" data-topicid="13310" href="/d/drug information/13310.html" rel="external">fluocinolone</a>) resulted in a higher rate of clinical cure at three weeks compared with either agent alone (81 versus 67 and 48 percent, respectively) [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H1069062"><span class="h4">Administration of ear drops</span><span class="headingEndMark"> — </span>Antibiotic ear drops work well when instilled into a thoroughly cleaned ear with a patent TT. It is less clear whether they work when applied over a collection of pus from a rapidly discharging AOM [<a href="#rid54">54,55</a>]. In an observational study using an in vitro model, ear drops instilled into a clean external ear canal did not consistently pass through the TT. Entry into the middle ear was facilitated by application of slight tragal pressure [<a href="#rid55">55</a>].</p><p>Ideally, the ear canal should be cleaned by the clinician with suction or repeated cotton swabbing before instilling drops. Having the child lie down with the affected ear up for a few moments promotes penetration. The optimal number of drops has not been established. According to the package inserts, the dose for <a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">ofloxacin</a> is five drops and the dose for <a class="drug drug_pediatric" data-topicid="12922" href="/d/drug information/12922.html" rel="external">ciprofloxacin-dexamethasone</a> is four drops. (See  <a class="medical medical_review" href="/d/html/91002.html" rel="external">"Chronic suppurative otitis media (CSOM): Treatment, complications, and prevention", section on 'Aural toilet'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Complicated acute tympanostomy tube otorrhea</span><span class="headingEndMark"> — </span>Complicated acute TTO refers to acute TTO in the setting of <strong>any</strong> of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Ill appearance, signs of systemic infection, or severe symptoms (eg, high fever, lethargy, severe ear pain)</p><p class="bulletIndent1"><span class="glyph">●</span>Auricular cellulitis</p><p class="bulletIndent1"><span class="glyph">●</span>Occlusion of the auditory canal</p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromise</p><p></p><p>For patients with complicated acute TTO, we suggest systemic (oral or parenteral) antibiotics for ill-appearing infants and older children with acute TTO and systemic infection or severe symptoms (eg, fever, lethargy, severe ear pain, copious otorrhea, associated upper respiratory symptoms) [<a href="#rid1">1,44</a>]. Antibiotic therapy should have activity against common AOM pathogens (eg, <em>S</em>. <em>pneumoniae</em>, <em>M</em>. <em>catarrhalis</em>, <em>H</em>. <em>influenzae</em>). We suggest high-dose <a class="drug drug_pediatric" data-topicid="12631" href="/d/drug information/12631.html" rel="external">amoxicillin</a> (75 to 100 mg/kg/day divided twice daily for 10 days) or <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> (with high-dose amoxicillin) as empiric therapy. (See  <a class="medical medical_review" href="/d/html/5959.html" rel="external">"Acute otitis media in children: Treatment", section on 'Initial antibiotic therapy'</a>.)</p><p>There are few high-quality studies assessing the efficacy of systemic antibiotic therapy for acute TTO in children [<a href="#rid39">39,56</a>]. In one small randomized trial, oral <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> was compared with placebo in 79 children with acute TTO of &lt;48 hours duration [<a href="#rid56">56</a>]. All patients underwent daily suctioning of middle ear fluid through the TT. Treatment with amoxicillin-clavulanate resulted in shorter duration of otorrhea (three versus eight days) and higher rate of resolution of otorrhea (82 versus 41 percent). However, the generalizability of these findings may be limited since it is not routine practice to perform daily suctioning in children treated with oral antibiotics [<a href="#rid39">39</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ill appearance and systemic symptoms</strong> – Ill-appearing infants may have concomitant systemic infection (eg, pneumonia, bacteremia) for which topical therapy has no effect. Bacterial culture of the discharge at the initiation of therapy may be useful in these children. Culture data can help guide antimicrobial therapy should empiric treatment fail. (See  <a class="medical medical_review" href="/d/html/6467.html" rel="external">"Approach to the ill-appearing infant (younger than 90 days of age)", section on 'Empiric therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated cellulitis</strong> – We suggest that children with acute TTO complicated by auricular cellulitis be treated with a combination of systemic and topical therapy. If possible, culture of the drainage should be obtained before antibiotic therapy is initiated. Empiric therapy should include oral antibiotics with activity against <em>S</em>. <em>aureus</em> and <em>S</em>. <em>pneumoniae</em> (eg, <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a>) in addition to topical antibiotics. Placing a porous wick in the inflamed ear canal may facilitate entry of the ototopic drop if the canal is occluded by secondary otitis externa [<a href="#rid57">57,58</a>]. (See <a class="local">'Pathogens'</a> above and  <a class="medical medical_review" href="/d/html/6866.html" rel="external">"External otitis: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Occluded auditory canal</strong> – The ability of topical therapy to reach the middle ear may be compromised in children with TTO complicated by occlusion of the auditory canal [<a href="#rid3">3</a>]. Occlusion may be caused by cerumen impaction or a foreign body. Empiric antimicrobial therapy in such cases should be based upon the most likely pathogens in the particular age group of the child. In addition, removal of the foreign body or obstructing cerumen may result in decreased otorrhea and improved access to the middle ear through the TT. (See <a class="local">'Pathogens'</a> above and  <a class="medical medical_review" href="/d/html/5959.html" rel="external">"Acute otitis media in children: Treatment", section on 'Initial antibiotic therapy'</a>.)</p><p></p><p class="bulletIndent1">If the child fails to respond with resolution of visible otorrhea within five days, we suggest the addition of an antibiotic ear drop with activity against <em>P</em>. <em>aeruginosa</em> and <em>S</em>. <em>aureus</em> (eg, a fluoroquinolone). If possible, the ear canal should be cleaned with an 8-French suction catheter and the discharge sent for culture and sensitivities before the ear drops are prescribed. (See <a class="local">'Uncomplicated acute tympanostomy tube otorrhea'</a> above.)</p><p></p><p class="bulletIndent1">If otorrhea persists three to five days after the addition of topical therapy, referral to a pediatric otolaryngologist is warranted for a thorough cleaning of the tube orifice and culture of the middle ear fluid. Management of persistent otorrhea is discussed below. (See <a class="local">'Chronic tympanostomy tube otorrhea'</a> below.)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">CHRONIC TYMPANOSTOMY TUBE OTORRHEA</span><span class="headingEndMark"> — </span>Chronic TTO refers to otorrhea that persists for six weeks with or without initial treatment with an ototopical antimicrobial and/or oral antibiotics. It develops in approximately 4 percent of patients after placement of TTs [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Causes</span><span class="headingEndMark"> — </span>A common cause of refractory TTO in children treated with topical agents is persistent bacterial infection due to inadequate penetration of the drops because of inspissated or accumulated debris in the ear canal. Most such cases resolve promptly after thorough cleaning, suctioning of the TT, and application of a topical corticosteroid-antibiotic drop for five to seven days.</p><p>Prolonged use of any topical antimicrobial, particularly broad-spectrum fluoroquinolones, may result in fungal overgrowth [<a href="#rid59">59,60</a>]. Children with fungal overgrowth present with thick fungal debris and clogged, itchy, or painful ears  (<a class="graphic graphic_picture graphicRef79646" href="/d/graphic/79646.html" rel="external">picture 3</a>).</p><p>Community-acquired methicillin-resistant <em>S</em>. <em>aureus</em> (CA-MRSA) and multiple drug-resistant <em>S</em>. <em>pneumoniae</em> are other potential causes of TTO refractory to the usual antimicrobial therapy described above [<a href="#rid61">61,62</a>]. (See  <a class="medical medical_review" href="/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum", section on 'CA-MRSA strains'</a>.)</p><p>Otorrhea persisting despite aural toilet (ie, suctioning of discharge from the ear canal), dry ear precautions, and intensive medical management may be caused by granulation tissue  (<a class="graphic graphic_picture graphicRef107997" href="/d/graphic/107997.html" rel="external">picture 2</a>), an occult cholesteatoma, or unusual pathogens, such as <em>Candida</em> <em>albicans</em>, <em>Actinomyces</em>, or <em>Aspergillus</em> [<a href="#rid59">59,60,63,64</a>]. Referral to an otolaryngologist is warranted in such patients to prevent the development of serious sequelae. (See  <a class="medical medical_review" href="/d/html/6306.html" rel="external">"Cholesteatoma in children"</a>.)</p><p>Other potential causes of chronic or recurrent TTO include immunodeficiency (particularly when associated with other upper and lower respiratory tract infections) and chronic adenoiditis [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/5949.html" rel="external">"Approach to the child with recurrent infections"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Management</span><span class="headingEndMark"> — </span>Children with chronic TTO should be referred to their otolaryngologist. It is desirable to directly suction the tube orifice under magnification to obtain middle ear discharge for culture and to ensure adequate cleaning [<a href="#rid65">65</a>]. If this is impossible because of equipment limitations or an apprehensive child, drying the ear canal with multiple cotton applicators or suctioning with a short flexible 8-French catheter are alternative ways to clear debris and permit entry of ear drops [<a href="#rid66">66</a>].</p><p>We recommend obtaining bacterial culture and sensitivities of the purulent drainage in the ear canal in cases of refractory otorrhea. A fungal stain/culture should also be ordered if the laboratory does not report common fungi on routine culture. Culture is particularly important for detection of resistant organisms (eg, CA-MRSA) or fungal overgrowth after prolonged antibiotic therapy. (See  <a class="medical medical_review" href="/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections", section on 'MRSA infections'</a>.)</p><p>We recommend that antimicrobial therapy for refractory otorrhea be based upon culture and susceptibility results. In one case series, fungal TTO was successfully treated with thorough cleaning under binocular microscopy and application of topical <a class="drug drug_pediatric" data-topicid="13173" href="/d/drug information/13173.html" rel="external">clotrimazole</a> solution [<a href="#rid60">60</a>]. Some patients required multiple treatments and/or systemic antifungal therapy (oral <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a> for seven days).</p><p>Successful eradication of refractory TTO caused by CA-MRSA has been reported with three regimens: oral <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> with topical <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a> or Cortisporin otic drops [<a href="#rid61">61</a>], <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> otic drops (not available in the United States) [<a href="#rid62">62</a>], and <a class="drug drug_pediatric" data-topicid="12622" href="/d/drug information/12622.html" rel="external">mupirocin</a> [<a href="#rid67">67,68</a>]. Mupirocin was not ototoxic in an animal model, but vancomycin was [<a href="#rid69">69</a>]. Several children who had CA-MRSA otorrhea were successfully treated with oral <a class="drug drug_pediatric" data-topicid="12555" href="/d/drug information/12555.html" rel="external">linezolid</a> [<a href="#rid70">70</a>]. Linezolid is available as a palatable oral suspension, but it is expensive. Parenteral antimicrobial therapy is warranted in some cases [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections", section on 'MRSA infections'</a>.)</p><p>Removing a TT is occasionally necessary to stop refractory otorrhea [<a href="#rid2">2,71,72</a>]. Bacterial biofilms can form on mucosal surfaces and implanted prostheses, including TTs  (<a class="graphic graphic_picture graphicRef69293" href="/d/graphic/69293.html" rel="external">picture 4</a>) [<a href="#rid73">73</a>]. These bacterial aggregates are resistant to therapy with systemic antibiotics and are not detected with standard culture methods. (See  <a class="medical medical_review" href="/d/html/6305.html" rel="external">"Overview of tympanostomy tube placement, postoperative care, and complications in children", section on 'Tube removal'</a>.)</p><p>Evaluation for possible immunodeficiency may be warranted in children with TTO caused by unusual pathogens, refractory chronic TTO, or frequent TTO in association with other upper and lower respiratory tract infections. (See  <a class="medical medical_review" href="/d/html/5949.html" rel="external">"Approach to the child with recurrent infections"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>For most patients, TTO is brief, painless, and not recurrent [<a href="#rid26">26</a>]. Chronic TTO develops in approximately 4 percent of patients after placement of TTs, and recurrent TTO develops in 7 percent [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2199033229"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109085.html" rel="external">"Society guideline links: Acute otitis media, otitis media with effusion, and external otitis"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Tympanostomy tube otorrhea (TTO) is defined as active drainage through an existing TT. Early-onset TTO occurs within two weeks of tube placement. Late-onset TTO occurs more than two weeks after tube placement. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For all children who undergo TT placement, we suggest administering topical fluoroquinolone ear drops (eg, <a class="drug drug_pediatric" data-topicid="12962" href="/d/drug information/12962.html" rel="external">ofloxacin</a> or <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> drops, with or without corticosteroid) postoperatively to prevent early-onset TTO (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternative options for prevention of early TTO include intraoperative multiple <a class="drug drug_pediatric" data-topicid="12796" href="/d/drug information/12796.html" rel="external">saline</a> washouts and an intraoperative single-dose application of topical antibiotic or antibiotic/corticosteroid drops. The dose and duration of postoperative topical antibiotic therapy depend upon whether there is evidence of active middle ear infection at the time of surgery. In patients without evidence of active infection, the regimen consists of five drops into the ear twice daily for three days postoperatively. If there is active middle ear infection at the time of surgery, the regimen consists of four drops into the ear twice daily for five to seven days. (See <a class="local">'Early onset'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of recurrent TTO in infants and young children involves the same measures used to control recurrent acute otitis media (AOM), including immunization, handwashing, and withdrawal from daycare, if feasible. (See  <a class="medical medical_review" href="/d/html/5998.html" rel="external">"Acute otitis media in children: Prevention of recurrence"</a> and  <a class="medical medical_review" href="/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines", section on 'Target groups'</a> and  <a class="medical medical_review" href="/d/html/6053.html" rel="external">"Pneumococcal vaccination in children", section on 'Routine immunization for children &lt;5 years'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Water precautions are not generally recommended, although they are advised in certain situations (eg, swimming in a lake, pond, river, or ocean; submerging in a bath; deep diving) and for certain patients (eg, those with active, recurrent, or prolonged otorrhea; those with a prior history of problems with water exposure). (See  <a class="medical medical_review" href="/d/html/6305.html" rel="external">"Overview of tympanostomy tube placement, postoperative care, and complications in children", section on 'Water precautions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children two years and younger, TTO is usually caused by <em>Streptococcus</em> <em>pneumoniae</em>, <em>Moraxella</em> <em>catarrhalis</em>, and <em>Haemophilus</em> <em>influenza</em>. In cases of persistent TTO and in older children in whom TTO is usually induced by water penetration, <em>Pseudomonas</em> <em>aeruginosa</em> and <em>Staphylococcus</em> <em>aureus</em> are more prevalent. (See <a class="local">'Acute tympanostomy tube otorrhea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of acute TTO depends upon whether the infection is uncomplicated or complicated (ie, associated with systemic symptoms, auricular cellulitis, occlusion of the auditory canal, or immunocompromise) (see <a class="local">'Treatment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with uncomplicated acute TTO, we suggest topical therapy with ear drops containing a fluoroquinolone plus a corticosteroid rather than topical aminoglycoside ear drops, oral antibiotics, or observation alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). A typical treatment regimen consists of <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>/<a class="drug drug_pediatric" data-topicid="13214" href="/d/drug information/13214.html" rel="external">dexamethasone</a> drops: four drops into the affected ear twice daily for five to seven days. If cost is an issue, ciprofloxacin 0.3% eye drops can be used in the ear with similar effect. Observation is a reasonable alternative for selected patients since some of these episodes resolve spontaneously. (See <a class="local">'Uncomplicated acute tympanostomy tube otorrhea'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with complicated acute TTO, we suggest systemic rather than topical antimicrobial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Empiric therapy typically consists of high-dose <a class="drug drug_pediatric" data-topicid="12631" href="/d/drug information/12631.html" rel="external">amoxicillin</a> (75 to 100 mg/kg/day divided twice daily for 10 days) or <a class="drug drug_pediatric" data-topicid="12639" href="/d/drug information/12639.html" rel="external">amoxicillin-clavulanate</a> (with high-dose amoxicillin). (See <a class="local">'Complicated acute tympanostomy tube otorrhea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with refractory TTO should be referred to their otolaryngologist for further evaluation and treatment. Antimicrobial therapy for refractory otorrhea should be based upon culture and sensitivity results. (See <a class="local">'Chronic tympanostomy tube otorrhea'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Oberman JP, Derkay CS. Posttympanostomy tube otorrhea. Am J Otolaryngol 2004; 25:110.</a></li><li><a class="nounderline abstract_t">Kay DJ, Nelson M, Rosenfeld RM. Meta-analysis of tympanostomy tube sequelae. Otolaryngol Head Neck Surg 2001; 124:374.</a></li><li><a class="nounderline abstract_t">Myer CM 3rd. Post-tympanostomy tube otorrhea. Ear Nose Throat J 2001; 80:4.</a></li><li><a class="nounderline abstract_t">Wang LC, Giddings CE, Phyland D. Predictors of postoperative complications in paediatric patients receiving grommets - A retrospective analysis. Int J Pediatr Otorhinolaryngol 2021; 142:110601.</a></li><li><a class="nounderline abstract_t">Alvi SA, Jones JW, Porter P, et al. Steroid Versus Antibiotic Drops in the Prevention of Postoperative Myringotomy Tube Complications. Ann Otol Rhinol Laryngol 2018; 127:445.</a></li><li><a class="nounderline abstract_t">Rosenfeld RM, Tunkel DE, Schwartz SR, et al. Executive Summary of Clinical Practice Guideline on Tympanostomy Tubes in Children (Update). Otolaryngol Head Neck Surg 2022; 166:189.</a></li><li><a class="nounderline abstract_t">Syed MI, Suller S, Browning GG, Akeroyd MA. Interventions for the prevention of postoperative ear discharge after insertion of ventilation tubes (grommets) in children. Cochrane Database Syst Rev 2013; :CD008512.</a></li><li><a class="nounderline abstract_t">Mair EA, Park AH, Don D, et al. Safety and Efficacy of Intratympanic Ciprofloxacin Otic Suspension in Children With Middle Ear Effusion Undergoing Tympanostomy Tube Placement: Two Randomized Clinical Trials. JAMA Otolaryngol Head Neck Surg 2016; 142:444.</a></li><li><a class="nounderline abstract_t">Park AH, White DR, Moss JR, et al. Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes. Otolaryngol Head Neck Surg 2016; 155:324.</a></li><li><a class="nounderline abstract_t">Poetker DM, Lindstrom DR, Patel NJ, et al. Ofloxacin otic drops vs neomycin-polymyxin B otic drops as prophylaxis against early postoperative tympanostomy tube otorrhea. Arch Otolaryngol Head Neck Surg 2006; 132:1294.</a></li><li><a class="nounderline abstract_t">Hochman J, Blakley B, Abdoh A, Aleid H. Post-tympanostomy tube otorrhea: a meta-analysis. Otolaryngol Head Neck Surg 2006; 135:8.</a></li><li><a class="nounderline abstract_t">Kumar VV, Gaughan J, Isaacson G, Szeremeta W. Oxymetazoline is equivalent to ciprofloxacin in preventing postoperative otorrhea or tympanostomy tube obstruction. Laryngoscope 2005; 115:363.</a></li><li><a class="nounderline abstract_t">Daniel SJ, Akinpelu OV, Sahmkow S, et al. Oxymetazoline ototoxicity in a chinchilla animal model. Otolaryngol Head Neck Surg 2012; 146:114.</a></li><li><a class="nounderline abstract_t">Isaacson G. Oxymetazoline, Mupirocin, Clotrimazole-Safe, Effective, Off-Label Agents for Tympanostomy Tube Care. Ear Nose Throat J 2020; 99:30S.</a></li><li><a class="nounderline abstract_t">Clark MP, Pangilinan L, Wang A, et al. The shelf life of antimicrobial ear drops. Laryngoscope 2010; 120:565.</a></li><li><a class="nounderline abstract_t">Gabarain G, Baird R, Morisada M, et al. Early Otorrhea Rates: A Randomized Trial of Ciprofloxacin versus Saline Drops after Tympanostomy Tubes. Ann Otol Rhinol Laryngol 2019; 128:760.</a></li><li><a class="nounderline abstract_t">Kocaturk S, Yardimci S, Yildirim A, Incesulu A. Preventive therapy for postoperative purulent otorrhea after ventilation tube insertion. Am J Otolaryngol 2005; 26:123.</a></li><li><a class="nounderline abstract_t">Morpeth JF, Bent JP, Watson T. A comparison of cortisporin and ciprofloxacin otic drops as prophylaxis against post-tympanostomy otorrhea. Int J Pediatr Otorhinolaryngol 2001; 61:99.</a></li><li><a class="nounderline abstract_t">Charnock DR. Early postoperative otorrhea after tympanostomy tube placement: a comparison of topical ophthalmic and otic drops. Ear Nose Throat J 1997; 76:870.</a></li><li><a class="nounderline abstract_t">Hester TO, Jones RO, Archer SM, Haydon RC. Prophylactic antibiotic drops after tympanostomy tube placement. Arch Otolaryngol Head Neck Surg 1995; 121:445.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207986Orig1s000ltr.pdf (Accessed on August 03, 2017).</li><li><a class="nounderline abstract_t">Niemelä M, Pihakari O, Pokka T, Uhari M. Pacifier as a risk factor for acute otitis media: A randomized, controlled trial of parental counseling. Pediatrics 2000; 106:483.</a></li><li><a class="nounderline abstract_t">Grijalva CG, Poehling KA, Nuorti JP, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006; 118:865.</a></li><li><a class="nounderline abstract_t">Ozgur SK, Beyazova U, Kemaloglu YK, et al. Effectiveness of inactivated influenza vaccine for prevention of otitis media in children. Pediatr Infect Dis J 2006; 25:401.</a></li><li><a class="nounderline abstract_t">Leach AJ, Morris PS. Antibiotics for the prevention of acute and chronic suppurative otitis media in children. Cochrane Database Syst Rev 2006; :CD004401.</a></li><li><a class="nounderline abstract_t">Mandel EM, Casselbrant ML, Kurs-Lasky M. Acute otorrhea: bacteriology of a common complication of tympanostomy tubes. Ann Otol Rhinol Laryngol 1994; 103:713.</a></li><li><a class="nounderline abstract_t">Schneider ML. Bacteriology of otorrhea from tympanostomy tubes. Arch Otolaryngol Head Neck Surg 1989; 115:1225.</a></li><li><a class="nounderline abstract_t">Granath A, Rynnel-Dagöö B, Backheden M, Lindberg K. Tube associated otorrhea in children with recurrent acute otitis media; results of a prospective randomized study on bacteriology and topical treatment with or without systemic antibiotics. Int J Pediatr Otorhinolaryngol 2008; 72:1225.</a></li><li><a class="nounderline abstract_t">Roland PS, Parry DA, Stroman DW. Microbiology of acute otitis media with tympanostomy tubes. Otolaryngol Head Neck Surg 2005; 133:585.</a></li><li><a class="nounderline abstract_t">van Dongen TM, Venekamp RP, Wensing AM, et al. Acute otorrhea in children with tympanostomy tubes: prevalence of bacteria and viruses in the post-pneumococcal conjugate vaccine era. Pediatr Infect Dis J 2015; 34:355.</a></li><li><a class="nounderline abstract_t">Fliss DM, Dagan R, Meidan N, Leiberman A. Aerobic bacteriology of chronic suppurative otitis media without cholesteatoma in children. Ann Otol Rhinol Laryngol 1992; 101:866.</a></li><li><a class="nounderline abstract_t">Wang JC, Pillutla P, Cordero J, Hamood AN. Prospective observational case series evaluating middle ear fluid and tympanostomy tubes through pyrosequencing. Int J Pediatr Otorhinolaryngol 2018; 114:159.</a></li><li><a class="nounderline abstract_t">Cheng J, Javia L. Methicillin-resistant Staphylococcus aureus (MRSA) pediatric tympanostomy tube otorrhea. Int J Pediatr Otorhinolaryngol 2012; 76:1795.</a></li><li><a class="nounderline abstract_t">Giebink GS, Daly K, Buran DJ, et al. Predictors for postoperative otorrhea following tympanostomy tube insertion. Arch Otolaryngol Head Neck Surg 1992; 118:491.</a></li><li><a class="nounderline abstract_t">Debruyne F, Jorissen M, Poelmans J. Otorrhea during transtympanal ventilation. Am J Otol 1988; 9:316.</a></li><li><a class="nounderline abstract_t">Scott BA, Strunk CL Jr. Posttympanostomy otorrhea: the efficacy of canal preparation. Laryngoscope 1992; 102:1103.</a></li><li><a class="nounderline abstract_t">van Dongen TM, van der Heijden GJ, Venekamp RP, et al. A trial of treatment for acute otorrhea in children with tympanostomy tubes. N Engl J Med 2014; 370:723.</a></li><li><a class="nounderline abstract_t">Rosenfeld RM, Tunkel DE, Schwartz SR, et al. Clinical Practice Guideline: Tympanostomy Tubes in Children (Update). Otolaryngol Head Neck Surg 2022; 166:S1.</a></li><li><a class="nounderline abstract_t">Vaile L, Williamson T, Waddell A, Taylor G. Interventions for ear discharge associated with grommets (ventilation tubes). Cochrane Database Syst Rev 2006; :CD001933.</a></li><li><a class="nounderline abstract_t">Isaacson G. Why don't those ear drops work for my patients? Pediatrics 2006; 118:1252.</a></li><li><a class="nounderline abstract_t">Schroeder A, Darrow DH. Management of the draining ear in children. Pediatr Ann 2004; 33:843.</a></li><li><a class="nounderline abstract_t">Daniel SJ, Munguia R. Ototoxicity of topical ciprofloxacin/dexamethasone otic suspension in a chinchilla animal model. Otolaryngol Head Neck Surg 2008; 139:840.</a></li><li><a class="nounderline abstract_t">Lemke LE, McGee DH, Prieskorn DM, et al. Safety of ciprofloxacin and dexamethasone in the guinea pig middle ear. Arch Otolaryngol Head Neck Surg 2009; 135:575.</a></li><li><a class="nounderline abstract_t">Daniel SJ, Kozak FK, Fabian MC, et al. Guidelines for the treatment of tympanostomy tube otorrhea. J Otolaryngol 2005; 34 Suppl 2:S60.</a></li><li><a class="nounderline abstract_t">Alrwisan A, Antonelli PJ, Winterstein AG. Quinolone Ear Drops After Tympanostomy Tubes and the Risk of Eardrum Perforation: A Retrospective Cohort Study. Clin Infect Dis 2017; 64:1052.</a></li><li><a class="nounderline abstract_t">Wang X, Winterstein AG, Alrwisan A, Antonelli PJ. Risk for Tympanic Membrane Perforation After Quinolone Ear Drops for Acute Otitis Externa. Clin Infect Dis 2020; 70:1103.</a></li><li><a class="nounderline abstract_t">Roland PS, Dohar JE, Lanier BJ, et al. Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of granulation tissue in children with acute otitis media with otorrhea through tympanostomy tubes. Otolaryngol Head Neck Surg 2004; 130:736.</a></li><li><a class="nounderline abstract_t">Roland PS, Anon JB, Moe RD, et al. Topical ciprofloxacin/dexamethasone is superior to ciprofloxacin alone in pediatric patients with acute otitis media and otorrhea through tympanostomy tubes. Laryngoscope 2003; 113:2116.</a></li><li><a class="nounderline abstract_t">Shaffer AD, Dohar JE. Evidence-based telehealth clinical pathway for pediatric tympanostomy tube otorrhea. Int J Pediatr Otorhinolaryngol 2020; 134:110027.</a></li><li><a class="nounderline abstract_t">Goldblatt EL, Dohar J, Nozza RJ, et al. Topical ofloxacin versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes. Int J Pediatr Otorhinolaryngol 1998; 46:91.</a></li><li><a class="nounderline abstract_t">Dohar J, Giles W, Roland P, et al. Topical ciprofloxacin/dexamethasone superior to oral amoxicillin/clavulanic acid in acute otitis media with otorrhea through tympanostomy tubes. Pediatrics 2006; 118:e561.</a></li><li><a class="nounderline abstract_t">Roland PS, Kreisler LS, Reese B, et al. Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of children with acute otitis media with otorrhea through tympanostomy tubes. Pediatrics 2004; 113:e40.</a></li><li><a class="nounderline abstract_t">Spektor Z, Pumarola F, Ismail K, et al. Efficacy and Safety of Ciprofloxacin Plus Fluocinolone in Otitis Media With Tympanostomy Tubes in Pediatric Patients: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg 2017; 143:341.</a></li><li><a class="nounderline abstract_t">Arnold DJ, Bressler KL. Permeability of tympanotomy tubes to ototopical preparations. Otolaryngol Head Neck Surg 1999; 121:35.</a></li><li><a class="nounderline abstract_t">Hebert RL 2nd, Vick ML, King GE, Bent JP 3rd. Tympanostomy tubes and otic suspensions: do they reach the middle ear space? Otolaryngol Head Neck Surg 2000; 122:330.</a></li><li><a class="nounderline abstract_t">Ruohola A, Heikkinen T, Meurman O, et al. Antibiotic treatment of acute otorrhea through tympanostomy tube: randomized double-blind placebo-controlled study with daily follow-up. Pediatrics 2003; 111:1061.</a></li><li><a class="nounderline abstract_t">Rosenfeld RM, Brown L, Cannon CR, et al. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg 2006; 134:S4.</a></li><li><a class="nounderline abstract_t">Dedhia K, Choi S, Chi DH. Management of refractory tympanostomy tube otorrhea with ear wicks. Laryngoscope 2015; 125:751.</a></li><li><a class="nounderline abstract_t">Cohen SR, Thompson JW. Otitic candidiasis in children: an evaluation of the problem and effectiveness of ketoconazole in 10 patients. Ann Otol Rhinol Laryngol 1990; 99:427.</a></li><li><a class="nounderline abstract_t">Schrader N, Isaacson G. Fungal otitis externa--its association with fluoroquinolone eardrops. Pediatrics 2003; 111:1123.</a></li><li><a class="nounderline abstract_t">Al-Shawwa BA, Wegner D. Trimethoprim-sulfamethoxazole plus topical antibiotics as therapy for acute otitis media with otorrhea caused by community-acquired methicillin-resistant Staphylococcus aureus in children. Arch Otolaryngol Head Neck Surg 2005; 131:782.</a></li><li><a class="nounderline abstract_t">Hwang JH, Tsai HY, Liu TC. Community-acquired methicillin-resistant Staphylococcus aureus infections in discharging ears. Acta Otolaryngol 2002; 122:827.</a></li><li><a class="nounderline abstract_t">Shelton C, Brackmann DE. Actinomycosis otitis media. Arch Otolaryngol Head Neck Surg 1988; 114:88.</a></li><li><a class="nounderline abstract_t">Hall PJ, Farrior JB. Aspergillus mastoiditis. Otolaryngol Head Neck Surg 1993; 108:167.</a></li><li><a class="nounderline abstract_t">Supance JS, Bluestone CD. "How I do it"--otology and neurotology. A specific issue and its solution. Medical management of the chronic draining ear. Laryngoscope 1983; 93:661.</a></li><li class="breakAll">Rosenfeld R, Isaacson G. Tympanostomy tube care and consequences. In: Evidence-based otitis media, Rosenfeld RM, Bluestone CD (Eds), BC Decker, Ontario 1999.</li><li><a class="nounderline abstract_t">Furukawa M, Minekawa A, Haruyama T, et al. Clinical effectiveness of ototopical application of mupirocin ointment in methicillin-resistant Staphylococcus aureus otorrhea. Otol Neurotol 2008; 29:676.</a></li><li><a class="nounderline abstract_t">Yankey H, Isaacson G. Efficacy of topical 2% mupirocin ointment for treatment of tympanostomy tube otorrhea caused by community-acquired methicillin resistant Staphylococcus aureus. Int J Pediatr Otorhinolaryngol 2018; 109:36.</a></li><li><a class="nounderline abstract_t">Rutherford KD, Kavanagh K, Parham K. Auditory function after application of ototopical vancomycin and mupirocin solutions in a murine model. Otolaryngol Head Neck Surg 2011; 144:419.</a></li><li><a class="nounderline abstract_t">Isaacson G, Aronoff SC. Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae. Int J Pediatr Otorhinolaryngol 2008; 72:647.</a></li><li><a class="nounderline abstract_t">Ah-Tye C, Paradise JL, Colborn DK. Otorrhea in young children after tympanostomy-tube placement for persistent middle-ear effusion: prevalence, incidence, and duration. Pediatrics 2001; 107:1251.</a></li><li><a class="nounderline abstract_t">Luxford WM, Sheehy JL. Myringotomy and ventilation tubes: a report of 1,568 ears. Laryngoscope 1982; 92:1293.</a></li><li><a class="nounderline abstract_t">Post JC. Direct evidence of bacterial biofilms in otitis media. Laryngoscope 2001; 111:2083.</a></li></ol></div><div id="topicVersionRevision">Topic 6295 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14976657" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Posttympanostomy tube otorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283489" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Meta-analysis of tympanostomy tube sequelae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11488078" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Post-tympanostomy tube otorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33412341" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Predictors of postoperative complications in paediatric patients receiving grommets - A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29807438" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Steroid Versus Antibiotic Drops in the Prevention of Postoperative Myringotomy Tube Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35138976" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Executive Summary of Clinical Practice Guideline on Tympanostomy Tubes in Children (Update).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633358" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Interventions for the prevention of postoperative ear discharge after insertion of ventilation tubes (grommets) in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26985629" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Safety and Efficacy of Intratympanic Ciprofloxacin Otic Suspension in Children With Middle Ear Effusion Undergoing Tympanostomy Tube Placement: Two Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27188702" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17178938" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ofloxacin otic drops vs neomycin-polymyxin B otic drops as prophylaxis against early postoperative tympanostomy tube otorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16815174" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Post-tympanostomy tube otorrhea: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689767" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Oxymetazoline is equivalent to ciprofloxacin in preventing postoperative otorrhea or tympanostomy tube obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21846927" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Oxymetazoline ototoxicity in a chinchilla animal model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32182136" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Oxymetazoline, Mupirocin, Clotrimazole-Safe, Effective, Off-Label Agents for Tympanostomy Tube Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20013841" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The shelf life of antimicrobial ear drops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30991815" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Early Otorrhea Rates: A Randomized Trial of Ciprofloxacin versus Saline Drops after Tympanostomy Tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15742266" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Preventive therapy for postoperative purulent otorrhea after ventilation tube insertion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11589975" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A comparison of cortisporin and ciprofloxacin otic drops as prophylaxis against post-tympanostomy otorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9431776" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Early postoperative otorrhea after tympanostomy tube placement: a comparison of topical ophthalmic and otic drops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7702820" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prophylactic antibiotic drops after tympanostomy tube placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7702820" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prophylactic antibiotic drops after tympanostomy tube placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10969091" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pacifier as a risk factor for acute otitis media: A randomized, controlled trial of parental counseling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950975" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645502" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effectiveness of inactivated influenza vaccine for prevention of otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054203" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antibiotics for the prevention of acute and chronic suppurative otitis media in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8085732" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acute otorrhea: bacteriology of a common complication of tympanostomy tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2789778" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bacteriology of otorrhea from tympanostomy tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18565598" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Tube associated otorrhea in children with recurrent acute otitis media; results of a prospective randomized study on bacteriology and topical treatment with or without systemic antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16213934" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Microbiology of acute otitis media with tympanostomy tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25764097" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acute otorrhea in children with tympanostomy tubes: prevalence of bacteria and viruses in the post-pneumococcal conjugate vaccine era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1416643" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Aerobic bacteriology of chronic suppurative otitis media without cholesteatoma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30262357" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prospective observational case series evaluating middle ear fluid and tympanostomy tubes through pyrosequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23021467" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Methicillin-resistant Staphylococcus aureus (MRSA) pediatric tympanostomy tube otorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571119" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Predictors for postoperative otorrhea following tympanostomy tube insertion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3177616" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Otorrhea during transtympanal ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1405960" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Posttympanostomy otorrhea: the efficacy of canal preparation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552319" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A trial of treatment for acute otorrhea in children with tympanostomy tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35138954" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical Practice Guideline: Tympanostomy Tubes in Children (Update).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625551" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Interventions for ear discharge associated with grommets (ventilation tubes).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16951020" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Why don't those ear drops work for my patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15615311" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Management of the draining ear in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19041513" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Ototoxicity of topical ciprofloxacin/dexamethasone otic suspension in a chinchilla animal model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528406" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Safety of ciprofloxacin and dexamethasone in the guinea pig middle ear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16076418" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Guidelines for the treatment of tympanostomy tube otorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329128" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Quinolone Ear Drops After Tympanostomy Tubes and the Risk of Eardrum Perforation: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31044229" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Risk for Tympanic Membrane Perforation After Quinolone Ear Drops for Acute Otitis Externa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15195060" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of granulation tissue in children with acute otitis media with otorrhea through tympanostomy tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14660913" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Topical ciprofloxacin/dexamethasone is superior to ciprofloxacin alone in pediatric patients with acute otitis media and otorrhea through tympanostomy tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32251973" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evidence-based telehealth clinical pathway for pediatric tympanostomy tube otorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190709" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Topical ofloxacin versus systemic amoxicillin/clavulanate in purulent otorrhea in children with tympanostomy tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16880248" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Topical ciprofloxacin/dexamethasone superior to oral amoxicillin/clavulanic acid in acute otitis media with otorrhea through tympanostomy tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14702493" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of children with acute otitis media with otorrhea through tympanostomy tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28006041" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy and Safety of Ciprofloxacin Plus Fluocinolone in Otitis Media With Tympanostomy Tubes in Pediatric Patients: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10388874" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Permeability of tympanotomy tubes to ototopical preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10699804" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Tympanostomy tubes and otic suspensions: do they reach the middle ear space?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12728089" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Antibiotic treatment of acute otorrhea through tympanostomy tube: randomized double-blind placebo-controlled study with daily follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638473" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical practice guideline: acute otitis externa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25215630" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Management of refractory tympanostomy tube otorrhea with ear wicks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2350126" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Otitic candidiasis in children: an evaluation of the problem and effectiveness of ketoconazole in 10 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12728096" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Fungal otitis externa--its association with fluoroquinolone eardrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172354" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Trimethoprim-sulfamethoxazole plus topical antibiotics as therapy for acute otitis media with otorrhea caused by community-acquired methicillin-resistant Staphylococcus aureus in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12542200" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Community-acquired methicillin-resistant Staphylococcus aureus infections in discharging ears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3334826" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Actinomycosis otitis media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8441542" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Aspergillus mastoiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6843264" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : "How I do it"--otology and neurotology. A specific issue and its solution. Medical management of the chronic draining ear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6843264" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : "How I do it"--otology and neurotology. A specific issue and its solution. Medical management of the chronic draining ear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18665032" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical effectiveness of ototopical application of mupirocin ointment in methicillin-resistant Staphylococcus aureus otorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29728181" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy of topical 2% mupirocin ointment for treatment of tympanostomy tube otorrhea caused by community-acquired methicillin resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493206" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Auditory function after application of ototopical vancomycin and mupirocin solutions in a murine model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18321598" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389239" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Otorrhea in young children after tympanostomy-tube placement for persistent middle-ear effusion: prevalence, incidence, and duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6890608" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Myringotomy and ventilation tubes: a report of 1,568 ears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11802002" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Direct evidence of bacterial biofilms in otitis media.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
